This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

In patent dispute between Teva, Amneal, professors file amicus brief with US appeals court

( August 30, 2024, 10:10 GMT | Official Statement) -- MLex Summary: Listing by Teva Branded Pharmaceutical Products R&D of five ProAir HFA inhaler patents in the US Food and Drug Administration's Orange Book of approved drugs represents a "classic case of evergreening," a group of 52 law, medicine and economics professors tell the US Court of Appeals for the Federal Circuit in an amicus curiae brief.  "Teva seeks to extend its exclusivity beyond the expiration of its core patents," they add. See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections